- Research article
- Open Access
Rheumatoid arthritis seropositive for the rheumatoid factor is linked to the protein tyrosine phosphatase nonreceptor 22-620W allele
Arthritis Research & Therapy volume 7, Article number: R1200 (2005)
The protein tyrosine phosphatase nonreceptor type 22 (PTPN22) gene encodes for lymphoid tyrosine phosphatase LYP, involved in the negative regulation of early T-cell activation. An association has recently been reported between the PTPN22-620W functional allele and rheumatoid factor-positive (RF+) rheumatoid arthritis (RA), among other autoimmune diseases. Expected linkage proof for consistency cannot be definitely produced by an affected sib-pair (ASP) analysis. Our aim was therefore to search for linkage evidence with the transmission disequilibrium test.
DNA from the French Caucasian population was available for two samples of 100 families with one RA patient and both parents, and for 88 RA index cases from RA ASP families. Genotyping was carried out by PCR-restriction fragment length polymorphism. The analysis was performed using the transmission disequilibrium test, genotype relative risk and ASP-based analysis.
The transmission disequilibrium test of the PTPN22-620W allele revealed linkage and association for RF+ RA (61% of transmission, P = 0.037). The genotype relative risk showed the risk allele in 34% of RF+ RA patients and in 24% of controls derived from nontransmitted parental chromosomes (P = 0.047, odds ratio = 1.69, 95% confidence interval = 1.03–2.78). The ASP investigation showed no enriched risk allele in RA multiplex families, resulting in a lack of power of ASP analysis, explaining the published negative results.
This study is the first to show linkage of PTPN22 to RF+ RA, consistent with PTPN22 as a new RA gene.
Rheumatoid arthritis (RA), the most common autoimmune disease, is thought to be a complex disease in which a combination of risk alleles from different susceptibility genes predisposes to the development of the disease, following exposure to as yet unknown environmental factors. Several genome scans have suggested multiple RA loci [1–8], and recent case-control association studies have suggested new RA genes [9, 10]. However, only HLA-DRB1 alleles have been both linked to and associated with RA, fulfilling the criteria for a fully demonstrated genetic factor .
A genetic association involving a functional polymorphism of the protein tyrosine phosphatase nonreceptor type 22 (PTPN22) gene was reported to be associated with rheumatoid factor-positive (RF+) RA, with type 1 diabetes, with systemic lupus erythematosus and with autoimmune thyroid disease [12–19]. The PTPN22 gene encodes for the intracellular tyrosine phosphatase LYP, which acts as a negative regulator of early T-cell activation through binding to the Csk protein [20, 21].
The PTPN22 single nucleotide polymorphism (SNP) (1858C/T) (rs 2476601) occurs as a result of an amino acid substitution of arginine for tryptophan at position 620 (R620W), in the P1 proline-rich domain. This domain is involved in the binding to the SH3 domain of Csk. Functional analysis showed that it affects the binding of LYP to Csk, leading to a lack of downregulation of T-cell activation, which is consistent with an increased susceptibility to autoimmunity for the 620W allele [12, 14].
The PTPN22-1858T allele has been reported to be associated with RF+ RA in several case-control studies [12, 18, 19, 22]. The first study, performed in a white North American population, reported an association between the PTPN22-1858T allele and RF+ sporadic RA (P = 6.6 × 10-4). This association was replicated in a different sample with multiplex RA cases (P = 5.6 × 10-8), the association being restricted to RF+ RA patients . The second study, also performed in a white North American population, compared the frequency of the PTPN22 risk allele between the Study of New Onset Rheumatoid Arthritis cohort and the control sample of the previous study , observing the association between the 1858T allele and early RF+ RA. The study also suggested a stronger association for the homozygous genotype 1858T/T . Three recent case-control studies performed in UK, Spanish and North-American Caucasian populations also found an association between the PTPN22-1858T allele and RA [18, 19, 23]. In contrast, the Spanish study observed no dose effect of the suspected allele . The UK study found an increased frequency of the suspected PTPN22 allele in the RF+ RA cases and suggested a stronger association for the homozygous genotype . The US study confirmed this association was restricted to RF+ RA and also showed a significantly higher risk for the homozygous genotype .
These findings provide strong evidence for the involvement of PTPN22 in RF+ RA susceptibility . The linkage proof is so far lacking, however, as the linkage analysis of the North American Rheumatoid Arthritis Consortium RA-affected sib-pairs resource for this PTPN22 SNP was inconclusive . The transmission disequilibrium test (TDT), simultaneously investigating linkage and association, is predicted to be more powerful than the affected sib-pair (ASP) analysis in demonstrating linkage for a factor such as PTPN22 [25, 26]. Three family-based association and linkage studies using TDT analysis were recently reported, providing linkage evidence of PTPN22 to type 1 diabetes [15, 27, 28]. The aim of the present study was to test this PTPN22 polymorphism for linkage to RF+ RA in the French Caucasian population, taking advantage of the TDT.
Patients and methods
Study design and study population
A TDT linkage study was conducted to investigate the PTPN22-1858C/T SNP in RA for one Caucasian population. RA patients and family members were recruited through a national media campaign in France, which was followed by the selection of individuals who fulfill the American College of Rheumatology (formerly the American Rheumatism Association) 1987 revised criteria for RA , according to the physician in charge of the patient. All clinical data were reviewed by rheumatologists from our team (SL, LM or P Fritz). All individuals provided informed consent and the ethics committee of the Hôpital Bicêtre approved the study.
Transmission disequilibrium test RA samples
Inclusion criteria for the two samples of the 100 French Caucasian families investigated here were the participation of one RA patient and both parents, as well as a French Caucasian origin of the family, defined by the four grandparents being French Caucasian. Families with an additional sibling with RA or RA patients who were younger than 18 years old were excluded. RA characteristics of index cases from TDT samples 1 and 2 are summarized in Table 1.
Affected sib-pair RA sample
The 88 index RA patients from the French Caucasian ASP families that had been analyzed for a refined genome scan were investigated in this study . Inclusion criteria for the sample of 88 families had been the participation of at least two siblings with RA and of French Caucasian origin, with all four grandparents being of European Caucasian origin. Families with RA patients younger than 18 years old were excluded. Of these 88 families, 81 had two affected siblings, six families had three affected siblings and one family had four affected siblings. Characteristics of the 88 RA index cases investigated in this study are summarized in Table 1. All ASP families had been previously genotyped for two microsatellite markers flanking the PTPN22 locus (D1S418 and D1S252) located at approximately -1 and +3 Mb, respectively, on either side of the PTPN22 locus, with heterozygosities of 80% and 81%, respectively [1, 30].
Molecular genotyping methods
Genomic DNA was purified from fresh peripheral blood leukocytes by standard methods . HLA-DRB1 typing (Dynal Classic high resolution and Sequence Specific Primers DR low resolution) and subtyping (Dynal Classic high resolution, for HLA-DRB1*01, HLA-DRB1*04, HLA-DRB1*11 and HLA-DRB1*13) were carried out using the PCR sequence-specific primers method (Dynal Biotech, Lake Success, NY, USA).
Genotyping of the PTPN22-1858C/T SNP was performed by PCR-restriction fragment length polymorphism. The sense and antisense primers were, respectively, 5'-GATAATGTTGCTTCAACGGAATTT-3' and 5'-CCATCCCACACTTTATTTTATACT-3'. The PTPN22-1858C/T transition at codon 620 eliminates a restriction site for RsAI in the 1858T allele. TDT RA sample 1 and sample 2 genotypes were checked with the PCR-restriction fragment length polymorphism using the XcmI enzyme, for which the 1858T allele creates a restriction site. Each genotype was interpreted independently by two of the investigators (EG and PD).
Rheumatoid factor status
The RF+ status was provided by the presence of at least one positive RF+ result during the disease course, as determined by latex fixation, by Waaler Rose assay or by laser nephelometry. The RF test was performed at least once for all TDT and ASP RA patients. The anti-cyclic citrullinated peptide status of RA patients was not available.
Hardy–Weinberg equilibrium check
The Hardy–Weinberg equilibrium of the PTPN22-1858C/T polymorphism was investigated using a chi-square test with one degree of freedom.
We planned a linkage test of the PTPN22-1858T allele RA hypothesis, restricted to RF+ RA patients. This hypothesis was first tested using the TDT RA sample 1. In case linkage was observed, or at least suggested, a replication test was planned with the TDT RA sample 2 and a global analysis for all TDT RA families. We also investigated the PTPN22 putative genotype in the index ASP RA sample, taking advantage of the linkage data available at the PTPN22 locus, as previously described .
Test for linkage and association in the TDT RA samples
Linkage and association analysis were performed using the TDT  and the genotype relative risk (GRR) test . The TDT compares the transmission of the SNP alleles from heterozygous parents to affected offspring, with Mendel's law expectation (50%), using a chi-square test with one degree of freedom. Similar to a case–control study, GRR compares the SNP genotypes distribution in RA cases and in 'controls' (controls are derived from nontransmitted parental chromosomes, for each family), using a chi-square test with the appropriate degree of freedom or the Fisher's exact test. P < 0.05 was considered significant.
Linkage-based test in the ASP RA sample 
Genetic factors are expected to be concentrated in families with multiples RA cases, such as ASP families. Within index RA cases, those sharing identical by descent chromosomes at the PTPN22 locus with their RA affected sib could be expected to concentrate further PTPN22 RA genetic factors. The putative PTPN22 genotypes were compared between the ASP RA index cases, the TDT RA cases and the controls from the TDT RA samples (controls are derived from nontransmitted parental chromosomes). For the linkage-based association test, the RF+ index cases that shared at least one allele identical by descent with their RF+ RA sib (IBD1 or IBD2) were used, taking advantage of the linkage data available at the PTPN22 locus .
Stratified linkage analysis based on the PTPN22-1858C/T genotypes
We conducted a linkage analysis using Allegro 1.1 software , taking into account the PTPN22-1858C/T genotypes, to select the subgroup of families with an index carrying the putative genotypes.
Assuming a PTPN22-1858T allele association similar to that of the North American population (14.8% allele frequency in RF+ RA cases and 8.7% in controls) , association analysis of our 100 TDT families (TDT RA sample 1) provides a 95% power to show a suggestion for association and a 53% power to reach statistical significance (P < 0.05). Our sample of 200 TDT families provides a 79% power for significance.
Hardy–Weinberg equilibrium check
The PTPN22-1858C/T polymorphism was in Hardy-Weinberg equilibrium in the control samples investigated.
Test for linkage and association in the TDT RA samples
TDT RA sample 1
The PTPN22-1858T allele was more frequent in the RF+ RA cases than in the controls: 20% versus 11% (P = 0.022, odds ratio [OR] = 2.05, 95% confidence interval [CI] = 1.1–3.8). The allele frequency observed in rheumatoid factor-negative (RF-) RA patients was 16%, compared with 10.5% in the resulting controls (P = 0.52). Significant linkage to RF+ RA was observed with an excess of transmission of the 1858T allele from heterozygous parents to RA cases (66% versus 50%, n = 47, P = 0.029) (Table 2). The GRR analysis revealed a statistically significant increase in the frequency of genotypes carrying the PTPN22-1858T allele (1858C/T + 1858T/T) in RF+ RA cases (35%) compared with controls (21%) (Table 3).
TDT RA sample 2
We observed an excess of transmission of the PTPN22-1858T allele to RF+ RA patients that was not significant (56%, P = 0.45) (Table 2). The GRR analysis showed a nonsignificant increase of the genotypes carrying the 1858T allele in RF+ RA patients compared with controls (Table 3).
Combined analysis of TDT samples
No statistically significant difference was observed between samples 1 and 2, allowing pooling for combined analysis. PTPN22 linkage to RF+ RA was significant (T-allele transmission, 61%; n = 90, P = 0.037). By contrast, transmission to RF- RA followed Mendel's law exactly (50%) (Table 2). The PTPN22-1858T allele frequency was significantly increased in RF+ RA compared with controls (19% versus 13%, P = 0.029, OR = 1.62, 95% CI = 1.05–2.50). The GRR analysis showed a significant increase of PTPN22 genotypes carrying the PTPN22-1858T allele in RF+ RA patients compared with controls (34% versus 24%, P = 0.047, OR = 1.69, 95% CI = 1.03–2.78). In the RF- RA patients, genotype frequencies were identical to those of controls, in keeping with the 50% transmission (Table 3).
No correlation between the HLA-DRB1 shared epitope status (DRB1*0101, DRB1*0102, DRB1*0401, DRB1*0404, DRB1*0405, DRB1*0408, DRB1*1001) and the PTPN22 genotypes in RF+ RA index cases was observed (Table 4). Apart from the RF status, no specific clinical features (erosive disease, age at disease onset) were found to be associated with the PTPN22-1858T/C or PTPN22-1858T/T genotypes (data not shown).
Linkage-based test in the RA multiplex ASP sample
The frequency of the PTPN22-1858T allele was similar in the RF+ ASP RA cases compared with the RF+ TDT RA cases (18% versus 19%). The linkage-based subgroup (IBD1 or IBD2) of RF+ RA index cases with concordant RF+ RA sibs showed no increase in the frequency of the suspected allele, compared with RF+ TDT RA cases. The GRR analysis was consistent with those findings, the PTPN22-1858C/T or PTPN22-1858T/T genotype frequency being equal between RF+ RA ASP index cases and RF+ RA TDT cases (Table 5).
Stratified linkage analysis at the PTPN22 locus based on the 1858C/T genotypes
Previous linkage analysis of these ASP families had shown no linkage at the PTPN22 locus (P = 0.74) . Stratified linkage analysis in RF+-concordant ASP, even after selection of the families with index cases carrying the PTPN22-1858C/T or PTPN22-1858T/T genotypes, still showed no linkage evidence at the PTPN22 locus (P = 0.69).
We searched for the PTPN22-1858T allele linkage to RF+ RA using the TDT, which simultaneously tests linkage and association, avoiding the major drawback of inevitable imperfect matching between cases and controls. Here, we provide linkage evidence for RF+ RA to the PTPN22-1858T allele. We also observed association with the PTPN22-1858C/T or PTPN22-1858T/T genotypes and we report for the first time an estimation of the association in the French Caucasian population for RF+ RA (34% versus 24%, P = 0.047, OR = 1.69, 95% CI = 1.03–2.78). In ASP RF+ RA index cases, the 1858C/T or 1858T/T genotype has a similar frequency as the TDT RF+ RA index cases. The association appears to be independent from the HLA-DRB1 shared epitope.
Our findings therefore provide linkage evidence in support of PTPN22 as a new RF+ RA genetic factor, concurring with previously reported case–control studies [12, 18, 19, 22, 23]. We extend this observation to the French Caucasian population, in which the magnitude of the association is similar.
The linkage evidence provided by this study remains statistically modest. Further linkage studies are needed to definitively establish linkage of the PTPN22-1858T allele to RF+ RA. For the observed transmission disequilibrium of 61%, a TDT sample size of 232 families would be required to obtain, with 80% power, an independent replication of the linkage evidence reported here.
Genome scans are popular as they do not require any a priori hypothesis to detect disease loci. They are clearly unable to detect all disease loci, however, especially factors such as PTPN22. The increased power of the TDT over the ASP analysis for such factors was predicted long ago . Our observation of the absence of a major increased frequency of the risk allele in multiplex ASP families when compared with sporadic cases, as reported by Begovich and colleagues , allows us to estimate the excess of allele sharing expected in the ASP analysis over the Mendel expectation of 50%. Using the estimation of the divergence from Mendel's law obtained from this study (61% transmission from heterozygous parents to RF+ RA patients, instead of 50%) and the genotype frequencies observed, the allele sharing expected is 52% for all families, 53% for the subgroup of RF+-concordant families and 56% for the small subgroup of RF+-concordant families with the 1858C/T or 1858T/T index case.
A huge sample size would therefore be required to demonstrate a significant excess of allele sharing over Mendel's law. In that regard, the PTPN22 situation is similar to that of the insulin gene in type 1 diabetes, for which the discrepancy between numerous association reports and the absence of linkage in ASP analysis was resolved using a TDT-like analysis . This explains the complete absence of linkage evidence that we observed in our ASP analysis, in keeping with the absence of clear ASP linkage reported by Begovich and colleagues . Further analysis using sophisticated software such as GIST might help clarify this point .
As indicated by Begovich and colleagues, the chromosome 1 linkage suggestion observed in the ASP analysis of the North American Rheumatoid Arthritis Consortium genome scan is not explained by the findings of the PTPN22 association . New RA genes detected by such linkage suggestions, which could be expected to be stronger RA factors, remain to be discovered. Hence the major interest in genome scan persists, despite the lack of power for some RA genes, such as PTPN22.
Interestingly, transmission of the 1858T allele to RF- RA cases precisely followed Mendel's law, with genotype frequencies identical to controls, strengthening the evidence that the PTPN22-620W role is restricted to RF+ RA [12, 19, 22, 23]. PTPN22 is probably the first example of a fully confirmed RA gene involved specifically in a precise aspect of RA clinical heterogeneity (RF+ RA). The absence of correlation between PTPN22 and HLA-DRB1 genotypes suggests that both RA genes could be involved in distinct gene combinations predisposing to RA, providing the first example of a clear genetic heterogeneity in RA.
Because the association is relatively modest, no genetic testing would be clinically indicated. Instead, the clinical relevance of the finding is likely to come through the better understanding of RA pathophysiology. It may lead to new therapeutic targets, aiming at the cause of RA, possibly shared by other autoimmune diseases.
Interestingly, all autoimmune diseases reported to be associated with the PTPN22-1858T allele are characterized by the production of autoantibodies [12–14, 16, 22], suggesting that the 620W variant of LYP could be implicated not only in T-cell activity regulation, but also in B-cell autoreactivity . It will consequently be of major interest to test further for association of the PTPN22-1858T allele in RA families with a clustering of multiple autoimmune diseases to measure precisely this association with each disease [38–41].
Our findings provide linkage evidence for the involvement of the PTPN22-1858T allele in RF+ RA genetic susceptibility, in the French Caucasian population, independent of HLA-DRB1. This is in keeping with the proposal of PTPN22 as a new RA susceptibility gene.
= affected sib-pair
= genotype relative risk
= polymerase chain reaction
= rheumatoid arthritis
= rheumatoid factor
= single nucleotide polymorphism
= transmission disequilibrium test.
Osorio YFJ, Bukulmez H, Petit-Teixeira E, Michou L, Pierlot C, Cailleau-Moindrault S, Lemaire I, Lasbleiz S, Alibert O, Quillet P, et al: Dense genome-wide linkage analysis of rheumatoid arthritis, including covariates. Arthritis Rheum. 2004, 50: 2757-2765. 10.1002/art.20458.
Shiozawa S, Hayashi S, Tsukamoto Y, Goko H, Kawasaki H, Wada T, Shimizu K, Yasuda N, Kamatani N, Takasugi K, et al: Identification of the gene loci that predispose to rheumatoid arthritis. Int Immunol. 1998, 10: 1891-1895. 10.1093/intimm/10.12.1891.
Cornelis F, Faure S, Martinez M, Prud'homme JF, Fritz P, Dib C, Alves H, Barrera P, de Vries N, Balsa A, et al: New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. Proc Natl Acad Sci USA. 1998, 95: 10746-10750. 10.1073/pnas.95.18.10746.
Jawaheer D, Seldin MF, Amos CI, Chen WV, Shigeta R, Etzel C, Damle A, Xiao X, Chen D, Lum RF, et al: Screening the genome for rheumatoid arthritis susceptibility genes: a replication study and combined analysis of 512 multicase families. Arthritis Rheum. 2003, 48: 906-916. 10.1002/art.10989.
John S, Shephard N, Liu G, Zeggini E, Cao M, Chen W, Vasavda N, Mills T, Barton A, Hinks A, et al: Whole-genome scan, in a complex disease, using 11,245 single-nucleotide polymorphisms: comparison with microsatellites. Am J Hum Genet. 2004, 75: 54-64. 10.1086/422195.
MacKay K, Eyre S, Myerscough A, Milicic A, Barton A, Laval S, Barrett J, Lee D, White S, John S, et al: Whole-genome linkage analysis of rheumatoid arthritis susceptibility loci in 252 affected sibling pairs in the United Kingdom. Arthritis Rheum. 2002, 46: 632-639. 10.1002/art.10147.
Jawaheer D, Seldin MF, Amos CI, Chen WV, Shigeta R, Monteiro J, Kern M, Criswell LA, Albani S, Nelson JL, et al: A genomewide screen in multiplex rheumatoid arthritis families suggests genetic overlap with other autoimmune diseases. Am J Hum Genet. 2001, 68: 927-936. 10.1086/319518.
Eyre S, Barton A, Shephard N, Hinks A, Brintnell W, MacKay K, Silman A, Ollier W, Wordsworth P, John S, Worthington J: Investigation of susceptibility loci identified in the UK rheumatoid arthritis whole-genome scan in a further series of 217 UK affected sibling pairs. Arthritis Rheum. 2004, 50: 729-735. 10.1002/art.20039.
Suzuki A, Yamada R, Chang X, Tokuhiro S, Sawada T, Suzuki M, Nagasaki M, Nakayama-Hamada M, Kawaida R, Ono M, et al: Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet. 2003, 34: 395-402. 10.1038/ng1206.
Tokuhiro S, Yamada R, Chang X, Suzuki A, Kochi Y, Sawada T, Suzuki M, Nagasaki M, Ohtsuki M, Ono M, et al: An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet. 2003, 35: 341-348. 10.1038/ng1267.
Seldin MF, Amos CI, Ward R, Gregersen PK: The genetics revolution and the assault on rheumatoid arthritis. Arthritis Rheum. 1999, 42: 1071-1079. 10.1002/1529-0131(199906)42:6<1071::AID-ANR1>3.0.CO;2-8.
Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC, Ardlie KG, Huang Q, Smith AM, Spoerke JM, et al: A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet. 2004, 75: 330-337. 10.1086/422827.
Kyogoku C, Langefeld CD, Ortmann WA, Lee A, Selby S, Carlton VE, Chang M, Ramos P, Baechler EC, Batliwalla FM, et al: Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet. 2004, 75: 504-507. 10.1086/423790.
Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M, MacMurray J, Meloni GF, Lucarelli P, Pellecchia M, et al: A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet. 2004, 36: 337-338. 10.1038/ng1323.
Smyth D, Cooper JD, Collins JE, Heward JM, Franklyn JA, Howson JM, Vella A, Nutland S, Rance HE, Maier L, et al: Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes. 2004, 53: 3020-3023.
Velaga MR, Wilson V, Jennings CE, Owen CJ, Herington S, Donaldson PT, Ball SG, James RA, Quinton R, Perros P, Pearce SH: The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. J Clin Endocrinol Metab. 2004, 89: 5862-5865. 10.1210/jc.2004-1108.
Onengut-Gumuscu S, Ewens KG, Spielman RS, Concannon P: A functional polymorphism (1858C/T) in the PTPN22 gene is linked and associated with type I diabetes in multiplex families. Genes Immun. 2004, 5: 678-680. 10.1038/sj.gene.6364138.
Orozco G, Sanchez E, Gonzalez-Gay MA, Lopez-Nevot MA, Torres B, Caliz R, Ortego-Centeno N, Jimenez-Alonso J, Pascual-Salcedo D, Balsa A, et al: Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum. 2005, 52: 219-224. 10.1002/art.20771.
Steer S, Lad B, Grumley JA, Kingsley GH, Fisher SA: Association of R602W in a protein tyrosine phosphatase gene with a high risk of rheumatoid arthritis in a British population: evidence for an early onset/disease severity effect. Arthritis Rheum. 2005, 52: 358-360. 10.1002/art.20737.
Cloutier JF, Veillette A: Association of inhibitory tyrosine protein kinase p50csk with protein tyrosine phosphatase PEP in T cells and other hemopoietic cells. EMBO J. 1996, 15: 4909-4918.
Cloutier JF, Veillette A: Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase. J Exp Med. 1999, 189: 111-121. 10.1084/jem.189.1.111.
Gregersen PK, Lee A, Begovich A, Massarotti E, Weisman M, Kent J, Bombardier C: A functional polymorphism of PTPN22 associates with seropositive but not seronegative rheumatoid arthritis in a cohort of patients with new onset RA (SONORA) [abstract]. Arthritis Rheum. 2004, S118-
Lee A, Li W, Liew A, Bombardier C, Weisman M, Massarotti E, Kent J, Wolfe F, Begovich A, Gregersen PK: The PTPN22 R620W polymorphism associates with RF positive rheumatoid arthritis in a dose-dependent manner but not with HLA-SE status. Genes Immun. 2005, 6: 129-133. 10.1038/sj.gene.6364159.
Siminovitch KA: PTPN22 and autoimmune disease. Nat Genet. 2004, 36: 1248-1249. 10.1038/ng1204-1248.
Spielman RS, Ewens WJ: The TDT and other family-based tests for linkage disequilibrium and association. Am J Hum Genet. 1996, 59: 983-989.
Risch N, Merikangas K: The future of genetic studies of complex human diseases. Science. 1996, 273: 1516-1517.
Qu H, Tessier MC, Hudson TJ, Polychronakos C: Confirmation of the association of the R620W polymorphism in the protein tyrosine phosphatase PTPN22 with type 1 diabetes in a family based study. J Med Genet. 2005, 42: 266-270. 10.1136/jmg.2004.026971.
Zhernakova A, Eerligh P, Wijmenga C, Barrera P, Roep BO, Koeleman BP: Differential association of the PTPN22 coding variant with autoimmune diseases in a Dutch population. Genes Immun. 2005, 10.1038/sj.gene.6364220.
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324.
Dib C, Faure S, Fizames C, Samson D, Drouot N, Vignal A, Millasseau P, Marc S, Hazan J, Seboun E, et al: A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature. 1996, 380: 152-154. 10.1038/380152a0.
Sambrook P, Fritsch E, Maniatis T: Molecular Cloning. A Laboratory Manual. Edited by: Cold Spring Harbor. 1989, New York: Cold Spring Harbor Laboratory Press, 1: 2
Dieude P, Petit E, Cailleau-Moindrault S, Osorio J, Pierlot C, Martinez M, Faure S, Alibert O, Lasbleiz S, De Toma C, et al: Association between tumor necrosis factor receptor II and familial, but not sporadic, rheumatoid arthritis: evidence for genetic heterogeneity. Arthritis Rheum. 2002, 46: 2039-2044. 10.1002/art.10101.
Spielman RS, McGinnis RE, Ewens WJ: Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet. 1993, 52: 506-516.
Lathrop GM: Estimating genotype relative risks. Tissue Antigens. 1983, 22: 160-166.
Gudbjartsson DF, Jonasson K, Frigge ML, Kong A: Allegro, a new computer program for multipoint linkage analysis. Nat Genet. 2000, 25: 12-13. 10.1038/75514.
Julier C, Hyer RN, Davies J, Merlin F, Soularue P, Briant L, Cathelineau G, Deschamps I, Rotter JI, Froguel P, et al: Insulin-IGF2 region on chromosome 11p encodes a gene implicated in HLA-DR4-dependent diabetes susceptibility. Nature. 1991, 354: 155-159. 10.1038/354155a0.
Li C, Scott LJ, Boehnke M: Assessing whether an allele can account in part for a linkage signal: the Genotype-IBD Sharing Test (GIST). Am J Hum Genet. 2004, 74: 418-431. 10.1086/381712.
Ittah M, Gottenberg JE, Proust A, Hachulla E, Puechal X, Loiseau P, Mariette X, Miceli-Richard C: No evidence for association between 1858 C/T single-nucleotide polymorphism of PTPN22 gene and primary Sjogren's syndrome. Genes Immun. 2005, 6: 457-458. 10.1038/sj.gene.6364229.
Criswell LA, Pfeiffer KA, Lum RF, Gonzales B, Novitzke J, Kern M, Moser KL, Begovich AB, Carlton VE, Li W, et al: Analysis of families in the Multiple Autoimmune Disease Genetics Consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am J Hum Genet. 2005, 76: 561-571. 10.1086/429096.
Hinks A, Barton A, John S, Bruce I, Hawkins C, Griffiths CE, Donn R, Thomson W, Silman A, Worthington J: Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. Arthritis Rheum. 2005, 52: 1694-1699. 10.1002/art.21049.
Skorka A, Bednarczuk T, Bar-Andziak E, Nauman J, Ploski R: Lymphoid tyrosine phosphatase (PTPN22/LYP) variant and Graves' disease in a Polish population: association and gene dose-dependent correlation with age of onset. Clin Endocrinol (Oxf). 2005, 62: 679-682. 10.1111/j.1365-2265.2005.02279.x.
The authors thank the patients, their families, their physicians and Dr P Fritz (Centre Viggo-Petersen, Hôpital Lariboisière, Paris, France) for their participation. For funding, the authors thank Association Française des Polyarthritiques, Association Rhumatisme et Travail, Association Polyarctique and Groupe Taitbout, Association de Recherche pour la Polyarthrite, Société Française de Rhumatologie, Genopole, Conseil Régional Ile de France, Faculté de Médecine Lariboisière Saint-Louis and Ministère de la Recherche et de l'Enseignement Supérieur. Institutional support from Shering-Plough, Amgen, Pfizer and Wyeth was gratefully received. The authors thank Dr JF Prudhomme, Dr C Bouchier and Professor J Weissenbach at Genethon and Dr C De Toma, MF Legrand and Professor G Thomas at Fondation Jean Dausset-CEPH for technical support. They also thank M Dieudé and C Robinson for critical reading of the manuscript (Hôpital Notre-Dame, Montreal, Québec, Canada).
The author(s) declare that they have no competing interests.
PD and SG carried out the molecular genetic studies. LM, EP-T, EG, CP, SL and FC performed acquisition of the data. PD, SG, LM, CP, BP and FC analyzed and interpreted the data. LM, SL and TB made a substantial contribution to the acquisition of clinical data and the follow-up of the patients. All authors read and approved the final manuscript.
Rights and permissions
About this article
Cite this article
Dieudé, P., Garnier, S., Michou, L. et al. Rheumatoid arthritis seropositive for the rheumatoid factor is linked to the protein tyrosine phosphatase nonreceptor 22-620W allele. Arthritis Res Ther 7, R1200 (2005). https://doi.org/10.1186/ar1812
- Rheumatoid Arthritis
- Rheumatoid Arthritis Patient
- Transmission Disequilibrium Test
- 1858T Allele
- Rheumatoid Arthritis Case